Cisplatin

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Cisplatin
   1. Pharmacist Assessment Report
   2. Cisplatin: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Cisplatin: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Cisplatin, so there is currently no new predicted indication. The 15 uses recorded for this drug are listed below. All of them are relations recorded in the knowledge graph, and none was found to be approved.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	15
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
borderline epithelial tumor of ovary
familial ovarian cancer
hereditary breast ovarian cancer syndrome
hereditary site-specific ovarian cancer syndrome
immature ovarian teratoma
maligant granulosa cell tumor of ovary
malignant dysgerminomatous germ cell tumor of ovary
malignant germ cell tumor of ovary
malignant non-dysgerminomatous germ cell tumor of ovary
malignant sertoli-leydig cell tumor of ovary
malignant sex cord stromal tumor of ovary
ovarian adenocarcinoma
ovarian cancer
ovarian carcinosarcoma
ovarian clear cell adenocarcinoma

Australia Market Information

Licence	Product	Dosage form	Status
4319H	Cisplatin Accord	I.V. injection 50 mg in 50 mL	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (platinum-based alkylating-like agent; forms DNA crosslinks)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the PI warnings and precautions (cisplatin is generally regarded as highly emetogenic)
Monitoring Items	Please refer to the PI; typically FBC, renal function, electrolytes, and hearing assessment
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Safety label data (warnings and contraindications) were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Drug Interactions: An interaction screen returned 100 potential interactions. Most of those listed are of moderate severity, with one minor. Examples include:

• Aminoglycoside antibiotics (for example kanamycin) and amphotericin B formulations (conventional, lipid complex, cholesteryl sulfate, liposomal)
• Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole)
• Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, beclomethasone)
• Mesalazine, balsalazide, metronidazole, exenatide
• Ascorbic acid (minor)

The data compiled do not describe the mechanism or clinical consequence of each interaction, so these should be checked against the PI and a current interaction reference.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---